Emmanuel Cosson, Marie Auzanneau, Gloria Aguayo, Wolfram Karges, et al. Poster. 17th International Conference on Advanced Technologies & Treatments for Diabetes. Florence, Italy (Mars 2024)
Background and Aims: We aimed to evaluate whether diabetes care and glucose control differ in men and women with type 1 diabetes (T1D) in two European countries.
Methods: We compared glucose data in adults with T1D in the DPV (n = 11,392, Germany, 17.1% university hospital, age 32 ± 17 years, diabetes duration 18 ± 14 years; 53.7% men) and SFDT1 studies (n = 1,259, France, age 40 ± 14 years, diabetes duration 23 ± 14 years; 54.2% men, 89.2% university hospital) in 2020‐2022.
Results: The use of continuous glucose monitoring (CGM) was 67.1% in DPV and 90.1% in SFDT1. More women than men were CGM users in DPV (69.1 vs 65.5%, respectively, p < 0.001) but not SFDT1 (90.0 vs 90.2%, respectively). In both countries, women were more prone than men to use continuous subcutaneous insulin infusion (DPV: 43.1 vs 32.0% respectively, p < 0.001; SFDT1: 29.3 vs 21.1%, p < 0.001); low‐glucose suspend (DPV: 12.1 vs 10.0%, p < 0.001; SFDT1: 17.7 vs 12.0%, p < 0.001) and hybrid closed loop systems (DPV: 9.7 vs 7.0%, p < 0.001; SFDT1: 9.0 vs 5.2%, p < 0.001). HbA1c levels were slightly lower in women in DPV (8.0 ± 1.7 vs 8.1 ± 1.9%, p = 0.009) while we observed comparable results in SFDT1 (7.9 ± 1.4 vs 7.8 ± 1.4%, p = 0.33). Time in range was higher in women in DPV (55 ± 18 vs 53 ± 19%, p = 0.045) with similar percentages in SFDT1 (56 ± 17 vs 58 ± 16%, p = 0.156). Time below range was similar in women as men in both countries.
Conclusions: In Germany and France, women appear to be more likely to use CGM and modern insulin delivery systems with better glucose control in women than men only in Germany.
(Poster) Emmanuel Cosson, Marie Auzanneau, Gloria Aguayo, Wolfram Karges, Jean‐Pierre Riveline, Svenja Meyhoefer, Laura Sablone, Sebastian Propp, Guy Fagherazzi and Reinhard W. Holl. EV209 / #1038 E‐Poster Topic: AS05. The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE.
Comments